Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis.
- Published in:
- 2003
- By:
- Publication type:
- journal article
Works by Hamrén, Bengt
Results: 27
1
2
Population pharmacokinetics of rosuvastatin in pediatric patients with heterozygous familial hypercholesterolemia.
- Published in:
- European Journal of Clinical Pharmacology, 2016, v. 72, n. 1, p. 19, doi. 10.1007/s00228-015-1946-4
- By:
- Publication type:
- Article
3
Dapagliflozin Pharmacokinetics Is Similar in Adults With Type 1 and Type 2 Diabetes Mellitus.
- Published in:
- Journal of Clinical Pharmacology, 2022, v. 62, n. 10, p. 1227, doi. 10.1002/jcph.2062
- By:
- Publication type:
- Article
4
Exposure–response modeling for nausea incidence for cotadutide using a Markov modeling approach.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2024, v. 13, n. 9, p. 1582, doi. 10.1002/psp4.13194
- By:
- Publication type:
- Article
5
A case‐study of model‐informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2022, v. 11, n. 12, p. 1569, doi. 10.1002/psp4.12866
- By:
- Publication type:
- Article
6
Quantifying the integrated physiological effects of endothelin-1 on cardiovascular and renal function in healthy subjects: a mathematical modeling analysis.
- Published in:
- Frontiers in Pharmacology, 2024, p. 1, doi. 10.3389/fphar.2024.1332394
- By:
- Publication type:
- Article
7
Model‐based characterization of the relationship between dapagliflozin systemic exposure and HbA1c response in patients with type 1 diabetes mellitus.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 6, p. 1381, doi. 10.1111/dom.13664
- By:
- Publication type:
- Article
8
Population pharmacokinetics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in atrial fibrillation patients receiving long-term anticoagulation therapy.
- Published in:
- 2006
- By:
- Publication type:
- journal article
9
Model selection and averaging of nonlinear mixed-effect models for robust phase III dose selection.
- Published in:
- Journal of Pharmacokinetics & Pharmacodynamics, 2017, v. 44, n. 6, p. 581, doi. 10.1007/s10928-017-9550-0
- By:
- Publication type:
- Article
10
Exposure-Response Analyses Supporting Ticagrelor Dosing Recommendation in Patients With Prior Myocardial Infarction.
- Published in:
- Journal of Clinical Pharmacology, 2017, v. 57, n. 5, p. 573, doi. 10.1002/jcph.839
- By:
- Publication type:
- Article
11
Pharmacokinetic-Pharmacodynamic Modeling of Fostamatinib Efficacy on ACR20 to Support Dose Selection in Patients With Rheumatoid Arthritis (RA)
- Published in:
- 2015
- By:
- Publication type:
- Journal Article
12
Pharmacokinetic-Pharmacodynamic Modeling of Fostamatinib Efficacy on ACR20 to Support Dose Selection in Patients With Rheumatoid Arthritis (RA).
- Published in:
- Journal of Clinical Pharmacology, 2015, v. 55, n. 3, p. 328, doi. 10.1002/jcph.406
- By:
- Publication type:
- Article
13
Pharmacokinetic-Pharmacodynamic Assessment of the Interrelationships Between Tesaglitazar Exposure and Renal Function in Patients With Type 2 Diabetes Mellitus.
- Published in:
- Journal of Clinical Pharmacology, 2012, v. 52, n. 9, p. 1317, doi. 10.1177/0091270011416937
- By:
- Publication type:
- Article
14
A Model for Glucose, Insulin, and Beta-Cell Dynamics in Subjects With Insulin Resistance and Patients With Type 2 Diabetes.
- Published in:
- Journal of Clinical Pharmacology, 2010, v. 50, n. 8, p. 861, doi. 10.1177/0091270009349711
- By:
- Publication type:
- Article
15
Integrating dose estimation into a decision‐making framework for model‐based drug development.
- Published in:
- Pharmaceutical Statistics, 2018, v. 17, n. 2, p. 155, doi. 10.1002/pst.1841
- By:
- Publication type:
- Article
16
Modelling and simulation to improve decision-making in clinical development.
- Published in:
- Pharmaceutical Statistics, 2005, v. 4, n. 1, p. 47, doi. 10.1002/pst.153
- By:
- Publication type:
- Article
17
Pharmacokinetic–pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients.
- Published in:
- British Journal of Clinical Pharmacology, 2019, v. 85, n. 2, p. 413, doi. 10.1111/bcp.13812
- By:
- Publication type:
- Article
18
Application of the integrated glucose-insulin model for cross-study characterization of T2DM patients on metformin background treatment.
- Published in:
- British Journal of Clinical Pharmacology, 2016, v. 82, n. 6, p. 1613, doi. 10.1111/bcp.13069
- By:
- Publication type:
- Article
19
Exposure-response for biomarkers of anticoagulant effects by the oral direct thrombin inhibitor AZD0837 in patients with atrial fibrillation.
- Published in:
- British Journal of Clinical Pharmacology, 2015, v. 80, n. 6, p. 1362, doi. 10.1111/bcp.12719
- By:
- Publication type:
- Article
20
Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function – evidence of interconversion.
- Published in:
- British Journal of Clinical Pharmacology, 2008, v. 65, n. 6, p. 855, doi. 10.1111/j.1365-2125.2008.03110.x
- By:
- Publication type:
- Article
21
Dose-Response Mixed Models for Repeated Measures – a New Method for Assessment of Dose-Response.
- Published in:
- Pharmaceutical Research, 2020, v. 37, n. 8, p. N.PAG, doi. 10.1007/s11095-020-02882-0
- By:
- Publication type:
- Article
22
Dapagliflozin pharmacokinetics is similar between patients with heart failure with reduced ejection fraction and patients with type 2 diabetes mellitus.
- Published in:
- British Journal of Clinical Pharmacology, 2024, v. 90, n. 2, p. 606, doi. 10.1111/bcp.15939
- By:
- Publication type:
- Article
23
Bilirubin levels and kidney function decline: An analysis of clinical trial and real world data.
- Published in:
- PLoS ONE, 2022, v. 17, n. 6, p. 1, doi. 10.1371/journal.pone.0269970
- By:
- Publication type:
- Article
24
Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial).
- Published in:
- PLoS ONE, 2021, v. 16, n. 11, p. 1, doi. 10.1371/journal.pone.0259372
- By:
- Publication type:
- Article
25
From Plan to Pivot: How Model‐Informed Drug Development Shaped the Dose Strategy of the Zibotentan/Dapagliflozin ZENITH Trials.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 116, n. 3, p. 653, doi. 10.1002/cpt.3362
- By:
- Publication type:
- Article
26
Population Pharmacokinetic Modeling of Cotadutide: A Dual Agonist Peptide of Glucagon-Like Peptide and Glucagon Receptors Administered to Participants with Type II Diabetes Mellitus, Chronic Kidney Disease, Obesity and Non-Alcoholic Steatohepatitis.
- Published in:
- Clinical Pharmacokinetics, 2024, v. 63, n. 2, p. 255, doi. 10.1007/s40262-023-01337-0
- By:
- Publication type:
- Article
27
Population Pharmacokinetics/Pharmacodynamics of Ticagrelor in Children with Sickle Cell Disease.
- Published in:
- 2019
- By:
- Publication type:
- journal article